Shares of Golden Star Resources Ltd. (NYSE:GSS) [Trend Analysis] swings enthusiastically in regular trading session, it a loss of -1.19% to close at $0.83. Golden Star Resources (GSS) reported ‘significant’ results from its Wassa Underground Gold Mine in Ghana.
First nine diamond drill results received from the 2016 B Shoot transverse stope drilling program. Significant intercepts included: 31.7 metres grading 23.8 grams per tonne of gold from 296.8m in hole BS16DD009. Moving forward to saw long-term intention, the experts calculate Return on Investment of -129.20%. The stock is going forward its fifty-two week low with 492.86% and lagging behind from its 52-week high price with -26.55%. GSS last month stock price volatility remained 7.88%.
Juno Therapeutics, Inc. (NASDAQ:JUNO) [Trend Analysis] retains strong position in active trade, as shares scoring -0.05% to $20.42 in a active trade session, while looking at the shares volume, around 4.2 Million shares have changed hands in this session. Juno Therapeutics (JUNO) reported that complete response and corresponding early survival data for JCAR014; Study data support the development of JCAR017 in CLL. The firm reports encouraging early data for JCAR014 in patients with chronic lymphocytic leukemia who failed treatment with ibrutinib. Insights from studies of the translational product, JCAR014, are being applied to the development of JCAR017 for the treatment of B-cell malignancies.
Both JCAR014 and JCAR017 use a 4-1BB co-stimulatory domain and defined 1:1 cell ratio of CD4:CD8 T cells. Key data for the flu/cy cohort include:Two of 24 (8%) patients developed grade 3-5 severe cytokine release syndrome (sCRS) and 6/24 (25%) patients developed grade 3-5 severe neurotoxicity. The most frequent severe Treatment Emergent Adverse Events were febrile neutropenia (75%), CRS (29%), fever (17%), lung infection (13%), encephalopathy (13%), and hypotension (13%). There was one treatment-related mortality (4%) in the trial in a patient who received flu/cy lymphodepletion, with both grade 5 CRS and cerebral edema. The firm has institutional ownership of 74.30%, while insider ownership included 4.30%. JUNO attains analyst recommendation of 2.30 with week’s performance of -7.69%. Investors looking further ahead will note that the Price to next year’s EPS is -7.50%.